Articles tagged with Cancer Immunotherapy
Researchers discovered that natural killer cells ramp up aerobic glycolysis about five days before T cells respond, shedding light on their role in mounting a rapid immune response. The findings have implications for using NK cells as immunotherapy in cancer treatment and cell therapy.
Cancer immunotherapy using acoustics-based therapies has shown synergistic effects, enhancing the autogenous immune response to cancer tissue. Detailed mechanisms of sonopyrolysis-, sonoporation-, and sonoluminescence-based therapy are discussed to demonstrate its potential in cancer treatment.
Researchers at UCSF have engineered smart immune cells effective against solid tumors, overcoming hurdles for immunotherapies. The new approach may be ready for clinical trials in the near future, offering hope for patients with previously untouchable cancers.
Researchers have discovered a new way to transform tissue surrounding prostate tumors to help the immune system fight cancer. The technique, called epigenetic reprogramming, could lead to improvements in immunotherapy treatments for prostate cancer.
Researchers have developed DeepTCR, a software package that employs deep-learning algorithms to analyze T-cell receptor sequencing data. The software can identify patterns in the receptors that confer the function of the T cell to recognize and kill pathological cells.
Researchers have identified a key protein, DAPK3, that plays a crucial role in the body's early immune response to cancer. The discovery highlights a new approach to cancer immunotherapy, where targeting the tumor's own innate immune system can help slow tumor growth and improve treatment outcomes.
A study analyzing 45 patients with Merkel cell carcinoma found that patients with shorter disease-free intervals and specific genetic mutations, such as ARID2 and NTRK1, may be more likely to benefit from immunotherapy. These findings could inform treatment decisions and future research.
Researchers have found that disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments. The new approach, targeting protein CD6, has shown promise in mice and may also treat autoimmune diseases.
Researchers developed a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach stimulates an immune response against cells with the loss of one gene copy, called loss of heterozygosity (LOH), and has shown promising results in laboratory studies and mouse models.
WEHI researchers have uncovered a process cells use to fight off infection and cancer that could pave the way for precision cancer immunotherapy treatment. The study found how the Flt3L hormone increases dendritic cell numbers, helping the immune system fight off cancer and infection.
Researchers at Massachusetts General Hospital found that a cosmetic laser can trigger local inflammation mimicking mutations, enhancing immune attacks against nonmutated tumor proteins. This approach could make immune checkpoint inhibitors effective against currently incurable cancers.
Researchers found that disrupting the effect of the tumor microenvironment on immune cells in mice allowed for shrinking tumors, prolonging survival and increasing sensitivity to immunotherapy. Silencing a key protein MCT1 caused tumor growth to slow down and killer T cells could attack cancer.
A new approach to extend probiotic survival in vivo is developed using Smectite, a drug commonly used for gastrointestinal diseases. The study found that Smectite promotes lactic acid bacteria (LAB) biofilm formation, leading to increased anti-tumour immune responses and improved immunotherapy efficacy.
Inherited genetic variation plays a role in who responds best to checkpoint inhibitors, which release the immune system's brakes. The study identified 22 regions or genes with significant effects on the immune system's response to cancer.
Researchers have made breakthroughs in engineering models of tumors to expand cancer immunotherapy's effectiveness. By modifying the cells in a patient's immune system, scientists aim to target cold or non-inflamed tumors.
Houston Methodist researchers created a mathematical model to predict how specific cancers will respond to immunotherapy treatments, enhancing chances for successful treatments. The model uses laws of physics and chemistry to describe complex biological systems involved in immunotherapy treatment and the associated immune response.
Researchers discovered that pancreatic cancer changes its microenvironment to evade immune cells, which can be reversed by targeting a specific protein called STAT1. This finding offers a new approach to immunotherapy for this deadly cancer.
Scientists at the University of Southampton have discovered that modifying antibodies to target OX40 can enhance immune responses against cancer cells. By adjusting the antibody's isotype, researchers found that one type can delete suppressive Treg cells and another can stimulate killer T-cells, leading to improved anti-tumor effects.
Researchers found that keeping STAT5 active in CAR T cells improves their persistence and tumor-killing ability. This breakthrough could lead to more effective cancer treatments, but further research is needed.
A large retrospective study found that patients with non-small cell lung cancer who developed two immune-related side effects had improved patient survival and delayed tumor progression. The researchers identified a correlation between multisystem immune-related adverse events and improved survival outcomes.
Scientists develop a new type of cancer immunotherapy that uses nanobiologics to train the innate immune system to eliminate tumor cells. The therapy targets the bone marrow and activates trained immunity, reprogramming bone marrow progenitor cells to produce immune cells that halt cancer growth.
Researchers at Memorial Sloan Kettering Cancer Center have discovered a new way to fight cancer by targeting the tumor microenvironment. By promoting wound healing and remodeling blood vessels, immune cells can starve tumors of nutrients and deprive them of growth factors.
Researchers at the University of South Australia have developed a novel microfluidic approach to purify CAR-T cells, reducing dead cells by over 70% and increasing cell viability by 20%. This method could significantly benefit patients by lowering manufacturing costs and side effects associated with CAR T cell therapy.
A novel combination of immunotherapy targeting CTLA-4 and PD-1 led to a rapid and complete response in a 19-year-old patient with stage 4 epithelioid sarcoma. The patient achieved complete remission within two weeks, resuming normal activities and physical examination.
Researchers discovered that liver tumors can harness the liver's powers to retrain the immune system and exert its influence on distant cancer cells. Adding a second checkpoint inhibitor in combination therapy may overcome this resistance and increase immunotherapy effectiveness.
Researchers identified 182 genes that regulate interaction between cancer and immune T cells, which could be harnessed for effective immunotherapy across different tumour types. The study also revealed the need for new therapy to account for genetic mutations in cancer cells that can make disease worse in response to treatment.
A clinical trial led by Fred Hutchinson Cancer Center found the iCanQuit app to be nearly 1.5 times more effective in helping adult smokers quit after 12 months compared to the National Cancer Institute's QuitGuide app. The study suggests that for every 100,000 smokers reached with iCanQuit, 28,000 would quit smoking.
A team of researchers developed a mathematical model that can determine the impact of the immune system on tumour evolution. The model predicts when cancer cells will activate their cloaking mechanisms against the immune system and informs on whether immunotherapy is likely to be effective.
The University of Louisville will establish a Center for Cancer Immunology and Immunotherapy to develop and improve cancer treatments that utilize the immune system. Researchers will focus on advancing strategies to use the immune response to fight cancer, with the goal of saving lives through immunotherapies.
Glioblastoma patients with mutated Wnt signaling exhibit increased PD-L1 production and reduced T cell infiltration. Targeting the Wnt pathway could improve immunotherapy's efficacy in treating various cancers.
A study found that a bacteriophage infecting enterococcus bacteria stimulates an immune response improving the efficacy of cancer treatments. Administration of enterococcus containing the bacteriophage boosted T cell responses in mice, and its presence was associated with improved survival following PD-1 immunotherapy.
Researchers discovered that removing copper from blood can destroy some deadly cancers resistant to immunotherapy. High levels of copper in cancer cells increase expression of PD-L1, a protein that hides cancer cells from the immune system.
Researchers have identified specific bacterial species that boost T-cell immunity and improve the effectiveness of immunotherapy in treating certain cancers. The discovery may lead to new treatments by harnessing the power of the microbiome to target cancer cells.
Researchers at Hollings Cancer Center are studying T-cell exhaustion in the tumor microenvironment to discover ways to revitalize immunity against tumors. The team's work may lead to a new approach for immunotherapy by targeting the stress response that undermines T-cell function.
Researchers discovered that a protein called Neuropilin-1 (NRP1) suppresses immune responses to cancer. Blocking NRP1 improves the immune system's ability to remember tumors, leading to better protection against recurrence and improved response to immunotherapy.
A ground-breaking clinical trial is underway at Sheba Medical Center in Israel to evaluate the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor. The trial aims to treat resistant metastatic melanoma, triple-negative breast cancer, renal cell carcinoma, and non-sm...
Researchers mapped out immune system of haematological malignancies to identify drug targets and patient groups for immunotherapies. Cytotoxic T and NK cells are abundant in certain subtypes, such as activated B cell-like B cell lymphoma and acute myeloid leukaemia.
New cost-effective technology enables advanced immunology studies on Tasmanian devils and reveals conserved immune pathways across 160 million years of evolution. The system can be applied to any vertebrate species, including humans.
Researchers from Fred Hutch and UW Medicine argue that treating COVID-19 early is crucial to preventing hospitalizations and deaths. They emphasize the importance of widely available home testing with nasal self-swabbing and rapid studies using viral-shedding metrics and symptoms.
City of Hope scientists have developed two potent small molecules, CS1 and CS2, which inhibit the FTO protein and suppress tumor growth in various cancers. The compounds demonstrate significant anti-tumor effects and improved overall survival in mice with acute myeloid leukemia and breast cancer.
A new treatment combination of immunotherapy and chemotherapy has been shown to improve overall survival by 20.4 months in patients with inoperable malignant pleural mesothelioma, exceeding the expected survival time of 12 months with chemotherapy alone.
Researchers at UCLA Jonsson Comprehensive Cancer Center found that combining toll-like receptor 9 agonists and NKTR-214 with PD-1 blockade can induce a potent immune reaction against resistant tumors. This combination therapy is being assessed in human clinical trials to improve cancer immunotherapy outcomes.
A phase III clinical trial has shown that immunotherapy drug 'avelumab' significantly improves survival in patients with the most common type of bladder cancer. Treatment with avelumab resulted in a 31% reduction in risk of death and extended median survival by over seven months.
A clinical trial led by Mount Sinai researchers showed that combining chemotherapy and immunotherapy can significantly delay the progression of metastatic bladder cancer. The trial also found that immunotherapy alone may be an option for patients with high PD-L1 protein expression in their tumors.
Researchers at Houston Methodist developed a clinically-applicable mathematical model to predict patient outcomes in cancer immunotherapy. The model uses CT-scan imaging data to identify patient-specific indicators of therapeutic response, correlating with anti-tumor immune state and tumor kill rates.
Researchers found that immunotherapy 'checkpoint' inhibitor treatment before surgery eliminated cancer evidence in nearly half of patients with Merkel cell carcinoma. The treatment approach may reduce surgery extent and slow tumor relapses.
A clinical trial found that immunotherapy significantly slowed the worsening of urothelial cancer when given after platinum-based chemotherapy, with a 60% longer time to cancer progression compared to the control group. The switch maintenance immunotherapy approach is expected to become a standard of care for metastatic bladder cancer.
A Phase II study found pembrolizumab to be effective in treating four rare cancer types with acceptable toxicity profiles. The treatment resulted in a median non-progression rate of 28% at 27 weeks, with complete response rates varying between 31-43% for each cancer type.
A study led by the University of Southampton found that a new drug, GKT137831, can break down the barrier preventing lymphocytes from attacking cancer cells. This approach may significantly improve the success rate of cancer immunotherapy treatment for many patients.
Yong Lu and David Soto-Pantoja receive grants to study immunotherapy and cardiotoxicity, aiming to improve cancer treatment outcomes and prevent heart disease. Their research could lead to new approaches in combating metastatic and treatment-resistant cancers.
Researchers at the University of Southampton have identified a potential link between new cancer treatments and tuberculosis. The study found that immune checkpoint inhibitors can lead to an excessive immune response, increasing the growth of bacteria that cause TB disease.
A new study has identified multiple factors contributing to osteosarcoma's poor responses to immunotherapy, including low immune cell infiltration and suppressed immune-stimulating neoantigens. The research provides insights into strategies for improving outcomes with immunotherapy in rare cancer types.
Researchers found that immune cells perceive each other's density to regulate their proliferation, leading to more efficient immune reactions. This mechanism could improve cancer immunotherapies by reducing the risk of excessive immune responses.
A cold plasma patch has been developed to deliver immune checkpoint inhibitors and cold plasma directly to tumors, boosting the immune response and killing cancer cells. The patch significantly prolonged survival and inhibited tumor growth in mice with melanoma.
A study suggests that combining NKTR-214 with adoptive cell therapy may produce a stronger immune response against advanced melanoma, increasing the number of anti-tumor immune cells and their lifespan. This approach could be effective for more patients with advanced solid tumors.
The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University aims to develop innovative solutions for cancer immunotherapy. The center will utilize a combination of tools from astronomy image analysis, pathology, computer science, cancer genomics, and immunogenomics.
Scientists at Sanford Burnham Prebys have discovered a new way to boost the immune system's ability to fight cancer. The study found that a PD-1 inhibitor can be used to treat tumors that currently do not respond to this therapy, when administered in mice lacking the Siah2 gene.
Researchers at University College London have identified a subset of immune cells that can kill cancerous cells, opening the door to new and more effective cancer treatments. The discovery builds on previous research and provides evidence for utilizing Blimp-1 to enhance anti-tumor activity in CD4+ T cells.
Researchers found that injecting seasonal flu vaccines into tumors in mice increased systemic immune responses and sensitivity to treatments. The results suggest that antipathogen vaccines may find additional benefit as cancer immunotherapies, potentially converting cold tumors to 'hot' states.
Researchers discovered immune cells inside tumor samples can predict progression-free survival after surgery for kidney cancer. Patients with well-supported immune cells have longer disease control, leading to improved treatment options and potential adjuvant therapy trials.